

STAND. COM. REP. NO.

848

Honolulu, Hawaii

MAR 05 , 2021

RE: H.B. No. 542

H.D. 1

Honorable Scott K. Saiki
Speaker, House of Representatives
Thirty-First State Legislature
Regular Session of 2021
State of Hawaii

Sir:

Your Committee on Consumer Protection & Commerce, to which
was referred H.B. No. 542 entitled:

"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED
SUBSTANCES ACT,"

begs leave to report as follows:

The purpose of this measure is to remove the prescription
drug Epidiolex and approved generic versions of that drug that
contain cannabidiol derived from cannabis and no more than 0.1
percent (w/w) residual tetrahydrocannabinols from schedule V of
the Uniform Controlled Substances Act.

Your Committee received testimony in support of this measure
from Greenwich Biosciences and one individual.

Your Committee finds that the Agriculture Improvement Act of
2018 (P.L. 115-334), modified the regulatory controls over
cannabis, tetrahydrocannabinols, and other cannabis-related
constituents in the federal Controlled Substances Act. In April
2020, the United States Drug Enforcement Agency notified the
manufacturer of Epidiolex of its removal from the federal
schedule V and officially removed its designation through an
interim final rule issued in August 2020. This measure is
necessary to conform the Uniform Controlled Substances Act with

2021-2048 HB542 HD1 HSCR HMSO



the federal treatment of Epidiolex and approved generic versions of that drug.

Your Committee has amended this measure by:

- (1) Changing the effective date to January 1, 2050, to encourage further discussion; and
- (2) Making technical, nonsubstantive amendments for the purposes of clarity, consistency, and style.

As affirmed by the record of votes of the members of your Committee on Consumer Protection & Commerce that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 542, as amended herein, and recommends that it pass Third Reading in the form attached hereto as H.B. No. 542, H.D. 1.

Respectfully submitted on
behalf of the members of the
Committee on Consumer
Protection & Commerce,



AARON LING JOHANSON, Chair



